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This chapter discusses the current evidence base for policies that could address socioeconomic status (SES) health
gradients in the United States. The present volume has documented an enormous amount of research on the linkages
between SES and health, but there are still relatively few studies that rigorously establish the effectiveness of particular
policies or interventions in reducing those gradients. Given the difficulty in developing randomized evidence for
many types of interventions related to social determinants of health, we argue for conducting policy analysis from a
Bayesian perspective. This Bayesian approach combines information on best available theory and evidence regarding
probable health benefits and costs of an intervention, providing a framework that also incorporates the probable
costs of inaction. The second half of the chapter adopts a ladder metaphor to classify policies and interventions that
could reduce SES gradients in population health. Using this framework, we consider the evidence base for various
types of policies, focusing primarily on the social determinants of health, under the rubric that “all policy is health
policy.” We conclude by discussing promising strategies for future strengthening of the evidence base for policy,
including the role of health impact assessment.
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Introduction
This volume has documented an enormous amount
of research on the linkages between socioeconomic
status (SES) and health. SES and health exhibit
strong relationships throughout time and place, and
across many dimensions of SES and health. In terms
of political science theories of policy stages, the
research community has clearly established that a
striking and highly troubling phenomenon exists.
As discussed in the Dow and Rehkopf chapter, these
SES gradients in health are worse in the United States
than in many other settings and have been worsen-
ing in recent decades. These gradients have been rec-
ognized by researchers for many years, and in some
settings have risen onto the agenda of policy makers,
though much more so in Europe and Canada than
in the United States. Once publicly acknowledged
by agenda setters as a problem, selecting effective
policies and interventions requires a deeper body of
evidence to point to the most promising approaches
for causally ameliorating the gradients.
Research advances highlighted in this volume
contribute to this policy formulation effort by elu-
cidating specific biological pathways by which SES
“gets under the skin” and influences health out-
comes. This helps establish where there are plau-
sible causal pathways running from SES to health,
helps guide development of appropriately targeted
interventions, and suggests outcomes to measure
for purposes of evaluating intervention effects. De-
spite this wealth of new research, however, the evi-
dence base includes few studies that rigorously es-
tablish the effectiveness of particular policies or
interventions based on strong experimental or
quasi-experimental causal designs. Indeed, rela-
tively few out of the thousands of SES health gradi-
ent studies are even able to convincingly tease out
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what portion of that observed relationship reflects
causal pathways from SES to health, as opposed to
the adverse SES effects of ill health, or third vari-
able explanations. Nevertheless, many in the field
believe that there is now a strong case in favor of
public policies targeting the social determinants of
health. How do we reconcile the paucity of strong
causal evidence with this strong support for policy
intervention?a
The next section of this chapter presents a cost–
benefit framework useful for addressing this ten-
sion as we move from evidence to policy, and argues
that in place of using statistical significance of ran-
domized trials as the paramount guide to policy, a
Bayesian policy analysis approach provides a more
appropriate framework for guiding decisions in this
arena. If the weight of theory and evidence sug-
gests that SES is likely to have substantial causal ef-
fects on population health, then even in the absence
of strong causal evidence, the Bayesian approach
in many cases may favor proactive policies and
interventions.
The latter half of the chapter uses a ladder
metaphor to illustrate a framework for classify-
a The tension about what policy implications are sup-
ported by the existing evidence base has at times been
presented as tension between disciplines. Economists
are sometimes characterized as overly dismissive of ob-
servational studies and hence reluctant to draw firm
policy conclusions about social determinants. Some
social epidemiologists have in turn been thought to al-
low personal preferences for redistribution to color their
interpretation of the strength of the evidence regarding
the extent to which redistribution would lead to im-
proved population health. Our extended interactions at
multidisciplinary meetings of the MacArthur Network
on SES and Health have suggested that these stereo-
types are often unfair. It is certainly likely that histor-
ically prevailing attitudes within disciplinary traditions
shape people’s predispositions when initially engaging
with this topic. While each discipline has its own set of
theoretical priors, prevailing attitudes, and preferred
methodological approaches, when engaged with the full
spectrum of evidence arising out of the many perspectives
represented in this volume, we have found that many of
the supposed disciplinary blinders recede. This experi-
ence (see chapter by Adler and Stewart in this volume on
the network process) reaffirms the importance of cross-
fertilization of ideas, approaches, and results across dis-
ciplinary silos in improving our ability to move from
research to informative policy debates.
ing various types of policies and interventions that
could reduce SES gradients in population health.
Using this framework, we consider the evidence base
for various types of policies, focusing primarily on
the social determinants of health, under the rubric
that “all policy is health policy.” We conclude by dis-
cussing promising strategies for strengthening the
evidence base for policy.
A framework for moving from
evidence to policy
Classical randomized trial approach
to evidence-based decisions
Across many disciplinary traditions, the random-
ized trial has been considered to yield the strongest
(most internally valid) level of evidence. The
Evidence-Based Medicine movement and its pre-
cursors have for many years emphasized random-
ized studies as providing the highest possible level of
evidence. To be recommended for adoption under
this approach, a treatment should ideally be shown
in a randomized trial to yield positive health bene-
fits at the 5% significance level. Recent reviews have
discussed application of these concepts to the re-
lated area of Evidence-Based Public Health.1,2 A
key difficulty highlighted is that while some pub-
lic health interventions are amenable to random-
ized study, many population-level social determi-
nant interventions have to date not been feasible
to study using randomization designs. If random-
ized evidence was required for policy decisions, then
this would remove many population-based inter-
ventions from consideration, in favor of more in-
dividualized interventions that are more amenable
to randomization, such as medical care.3 However,
other researchers have argued that the lack of ran-
domized trial results should not imply lack of ac-
tion; decisions still must be made, and should use
the best available evidence.4 In fact, many health
policies and interventions are based on evidence
that is relatively weak or sometimes missing alto-
gether. While the evidence base in both medicine
and public health is growing, it is still relatively lim-
ited. A majority of medical practices have weak to no
formal evaluation.5 Within public health, a recent
study found that more than 40% of programs lack
an evidence base.6 Thus while it is of course desir-
able to have the strongest evidence possible, it would
be a counterproductive double standard to insist on
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randomized evidence before backing any policies or
interventions relating to the social determinants of
health.
Potts et al. went further than this, arguing that
where nonexperimental evidence is strongly sug-
gestive, it would be unethical not to act.7 They ap-
provingly cite Smith and Pell’s satirical essay that
provocatively argues that because randomized tri-
als have not proven the efficacy of parachutes, they
should not be used until a randomized, placebo-
controlled parachute trial has been conducted.8 Ex-
tensive commentary in letters submitted to the jour-
nal in response criticized Potts et al., however, on
two key counts. First, there was concern about possi-
ble cherry picking of the nonexperimental evidence
in support of some favored approach. Indeed, Ioan-
nidis warns that nonrandomized studies may sys-
tematically produce larger results than randomized
ones, presumably due to data mining (possibly in-
advertent) and publication bias problems, and that
“claimed research findings may often be simply ac-
curate measures of the prevailing bias” in a field.9,10
Randomized trials do not wholly avoid this prob-
lem, however, as their design and framing may re-
flect underlying assumptions and they often pro-
duce conflicting results. Concern about publication
bias and data mining highlights the importance of
critical, comprehensive, and balanced literature re-
views; however, it should not preclude the use of
nonexperimental evidence when it is the best avail-
able for policy. A second critique of the Potts et al.
approach is potentially more serious: that the health
field is replete with examples of poorly tested and
now discontinued practices and interventions that
have turned out to be useless or even harmful on net
after further study. However, such cases are not the
norm, and this critique ignores the many medical
practices that have turned out to indeed be benefi-
cial despite lack of early rigorous testing. What these
concerns highlight is the importance of having a
framework for prospectively using the best available
information to choose which interventions are ex-
pected to have net benefits that are greater than net
costs.
Decision science and Bayesian policy analysis
Here, we turn to the field of Decision Science, an
area of study devoted to making optimal use of
evidence for decision making, based on the tools
of cost-effectiveness, cost-utility, and cost–benefit
analysis.11 A considerable portion of this field has
focused on decisions about clinical medicine, but
similar conceptual principles apply to nonmedical
health policies. Among the most important concep-
tual differences between decision analysis and the
traditional focus on randomized trials is that un-
like classical statistics, decision analysis does not fo-
cus solely on 5% significance levels to determine
whether an intervention is recommended. Cost–
benefit analysis (the conceptually most appropriate
but most challenging decision science method in
practice), is guided instead by an analysis of whether,
after appropriately considering all of the benefits
and costs of a policy or intervention, and their esti-
mated uncertainty, the expected benefits outweigh
the expected costs.
Consider an intervention that would increase
health by H units over the status quo, at an in-
cremental cost of C. To reflect uncertainty about
our estimates, the future time path of benefits, and
the value of health, we will represent the health im-
provement as having a present discounted (i.e., as
valued today) expected value of EV[H]. Similarly,
represent the present discounted expected value of
intervention costs as EV[C]. The benefit–cost de-
cision rule would be to recommend this intervention
for populations where: EV[H] > EV[C]. Note
that proponents of an intervention often argue that
the “cost of inaction” (maintaining the status quo)
must be considered as well. This cost of inaction is
already incorporated into the decision rule, as it typ-
ically refers to the value of the foregone health im-
provement, EV[H], which would not be obtained
if the intervention were not to be adopted. But it is
useful to state in both manners, as a reminder to fo-
cus not just on the costs of the intervention EV[C],
but to instead compare which of these amounts is
larger. More precisely, the net “cost of inaction” can
be defined as EV[H] − EV[C]; that is, the net
surplus to society that would be foregone if the in-
tervention were not adopted
Actual estimation of the full EV[H] and
EV[C] is of course complex, but focusing here on
this simple relation is instructive for thinking about
common features of policies and interventions dis-
cussed in the latter half of the chapter. Consider
what is included in the cost calculation EV[C].
As the cost-effectiveness literature has emphasized,
this should capture any incremental change in direct
and indirect costs, both now and in the future, as
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compared to what costs would have been in the ab-
sence of the intervention. Whose costs are included
will depend on whether the analysis is from the
perspective of an individual, family, or some larger
population group. A typical population health anal-
ysis might take the perspective of the nation, thus
include both personal and public budgetary costs
of everyone in the nation. From this perspective,
any unintended efficiency loss caused by the inter-
vention should also be taken into account. For in-
terventions with public budgetary costs (including
many key social determinants discussed below), an
important efficiency loss to take into account would
be the “marginal cost of public funds”;12 that is,
the welfare loss from reduced work effort caused by
raising taxes. Raising $1 of budget revenue may cost
the economy $1.15 for a relatively nondistortionary
tax, or it could cost substantially more for other
types of taxes that have bigger negative impacts on
behavior. It would also be appropriate to include
among the costs any other losses induced by the
program, such as negative work incentives induced
by means-testing programs; in practice, however,
such costs are rarely estimated and thus are left to
be considered more qualitatively alongside the nu-
meric benefit–cost result.
Calculation of benefits EV[H] also requires
careful consideration. Many health investments may
not pay off for many years, while costs are incurred
upfront, thus benefits may be less striking after ap-
propriately discounting. For example, if an early
childhood program improves chronic disease out-
comes by one unit when the child reaches age 50,
then discounting at 3% annually yields a present
value of that improvement equal to less than one-
fourth of a unit. At the same time, when considering
health benefits of nonhealth policies, it is important
to take into account the value of nonhealth benefits
as well. For example, Dow and Schoeni13 calculated
the EV[H] of health improvements from invest-
ing in college education so as to raise the health of
less educated Americans up to the level of college-
educated Americans; the health benefit was roughly
one trillion dollars, but the wage benefit of educa-
tion would likely be valued at more than double
this amount. This finding, that the health value of
nonhealth policy may be somewhat smaller than
the nonhealth value, may be common when exam-
ining policies targeted at the social determinants of
health. To accomplish a full analysis across different
types of outcomes, it is necessary to use a common
economic value metric. It is tempting to cite the
health benefits only in health units, such as reduced
asthma cases or increased quality-adjusted life years
(QALYs), but comparing the full costs and benefits
of such policies will require going the next step and
placing a dollar value on health (e.g., the commonly
used value of $100,000 per QALY). Valuing both
health and nonhealth benefits is likely to result in
more favorable assessments of the benefits of such
policies.
What about the many sources of uncertainty in
decision science analyses? Best practice in decision
science modeling involves extensive sensitivity anal-
ysis. One type of sensitivity is with respect to model-
ing decisions and assumptions, such as the value of
a QALY. A second type of sensitivity is with respect
to statistical uncertainty surrounding the value of
parameter inputs, such as the estimated effective-
ness of an intervention on health. Stochastic deci-
sion analysis techniques have been developed from
either a classical frequentist perspective, using tra-
ditional confidence intervals from a randomized
trial, or alternatively from a Bayesian perspective
using a prior distribution influenced by both con-
fidence intervals and potentially subjective factors,
such as strength of study design as well as theo-
retical priors. While one could insist on only us-
ing classical statistical inference from randomized
trials when conducting decision analyses, such ap-
proaches are in the minority; a Bayesian-like choice
of sensitivity thresholds has long been employed,
and formal Bayesian practices are now emerging as
well.14–16
In fact, Claxton goes one step further, arguing
for a full Bayesian-theoretic decision approach in
which decisions are based only on whether mean net
benefit is positive (EV[H] > EV[C]), regardless
of confidence intervals (surrounding, for example,
the estimate of the health effect H).17 When a
policy decision must be made, he argues that the
best available estimates should be used and acted
upon, without favoring one outcome over another
based solely on arbitrary significance level choices.
Claxton, Neumann, Araki, and Weinstein (2001)
provide an example in which relying on a classical
approach insisting on 5% significance levels would
result in an unduly conservative decision to
withhold an Alzheimer’s treatment, and thus would
result in net harm to the population.18 It is
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Figure 1. Illustrative Bayesian distributions of health improvements from interventions.
important to note though that this does not imply
that confidence intervals and quality of evidence are
irrelevant—on the contrary, in a Bayesian analysis
the quality of evidence is likely to factor even more
importantly than in a classical statistical paradigm.
In a Bayesian policy analysis, an analyst begins
with theoretical arguments and evidence from re-
lated areas to form a prior distribution (i.e., prior
to bringing to bear direct evidence on the pol-
icy) of the likely net empirical effect of the pol-
icy (on H and C), Although we discuss this
prior distribution in formal statistical terms, it is
of course common that these priors are held quite
informally (by both researchers and policy mak-
ers). In a situation in which the analyst has a rel-
atively diffuse prior, acknowledging, for example,
the theoretical potential that the intervention has
some chance of either helping or harming health,
then before considering the weight of evidence,
the analyst’s prior is likely to be that a costly in-
tervention would not yield net benefit. This situ-
ation is illustrated in the left-most distribution of
Figure 1, which depicts a probability density func-
tion of the likelihood that the net health effects of an
intervention would take on various values. The prior
distribution of Figure 1 shows a mean estimated
net health benefit that is positive (size one unit),
but with considerable uncertainty. As new evidence
develops, the analyst uses this new knowledge to
update this prior distribution, resulting in a new
“posterior distribution” (reflecting the original
theoretical information plus the new empirical
evidence) of the net health benefits. If a strong ran-
domized trial were conducted that precisely esti-
mated large benefits, of say a magnitude four units
net health improvement in the Figure 1 example,
then the posterior distribution of H might be-
come quite tight and pulled close to that estimate.
This is illustrated by the right-most (strong) poste-
rior distribution in Figure 1, which results in an
updated mean effect of three units. If the costs
are less than three units, then the Bayesian analy-
sis might accord well with the classical analysis. But
if instead only a small observational study is avail-
able, even if it estimated the same effect size of four
units, the prior distribution would not be moved as
far to the right. Instead, the prior distribution may
only weakly move to the right, as in the posterior
distribution in the middle of Figure 1, which de-
picts an updated mean of two units. In this case,
depending on the net cost, the Bayesian analysis
may or may not yield an estimate that EV[H] >
EV[C]. If the net cost were greater than two units
then the Bayesian analysis would accord with a clas-
sical perspective, but if costs were below two units
then even in the absence of a strong randomized trial
the Bayesian analysis would support the policy pro-
posal. Thus in Bayesian policy analysis, the validity
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and precision of estimatedH only indirectly affects
the policy recommendation, rather than dominat-
ing it. Instead of solely focusing on the statistical sig-
nificance of randomized trial evidence, the Bayesian
policy analysis is better able to incorporate both the-
oretical priors and weaker types of evidence, as well
as the crucial information on intervention costs.
Finally, Claxton points out that this same
Bayesian method of indirectly incorporating study
quality and confidence intervals may be used to de-
rive the value of producing additional research on
H , by estimating how likely different types of new
evidence would be to substantially move the poste-
rior distribution. Thus the Bayesian approach has
the further benefit of helping guide efficient invest-
ment into future research agendas.
We next turn to considering types of policies and
interventions that could reduce socioeconomic dis-
parities in health. Many of these have characteris-
tics discussed above. They generally lack evidence
from randomized trials, while having varying de-
grees of observational evidence, as well as varying
levels of theoretical agreement regarding likely or-
ders of magnitude and direction of effects. The fea-
sibility of conducting various types of decision anal-
ysis will also vary across these interventions. As of
yet there are no formal Bayesian policy analyses to
report, and given the nature of the political pro-
cesses in which the evidence must be used, formal
Bayesian analyses are unlikely to gain widespread
use in considering these policies beyond the re-
search community. But the conceptual framework
of Bayesian policy analysis is crucial to apply even
if informally: combining all available information
from theory, randomized trials, and observational
studies will provide a stronger basis for choosing
those policies and interventions with the highest
expected positive social benefit after accounting for
full social costs.
A taxonomy of policies and interventions
to reduce socioeconomic status gradients
in health
A society can attempt to reduce SES-health gradients
in many different ways. Here, we use the metaphor
of the ladder (referred to elsewhere in the volume)
to classify different types of policy options. Assume
that the ladder reflects the SES distribution in a so-
ciety, from low SES (bottom of the ladder) to high
(top of the ladder), with the 10 rungs of the ladder
indicating the SES level of the 10 SES deciles. In
Figure 2A, the 10 connected data points can be
thought of as a curved SES ladder superimposed
on a graph showing health on the vertical axis as a
function of SES on the horizontal axis. The figure
depicts the health gradient as nonlinear, diminish-
ing with SES but still upward sloping even between
the highest two rungs.
As we discuss each policy domain, we refer to
current evidence on the impact of such policies
on health; in some cases the evidence has already
been examined in this volume (e.g., income and
education in the Kawachi chapter). As Brownson
et al. discuss,1,2 however, there are now a variety of
organizations that provide public health evidence
summaries, such as the Centers for Disease Con-
trol and Prevention’s (CDC’s) Guide to Community
Preventive Services,19 and we do not duplicate those
summaries here. For many of the types of policy
examples mentioned below, however, there are no
evidence summaries.
In fact, for some of these nonhealth social poli-
cies, the health implications remain relatively un-
explored (e.g., effects of school quality). For some
types of nonhealth policies, this is not surprising be-
cause nonhealth analysts have not appreciated the
potential impacts on health, and health outcomes
are not their central concern. This is unfortunate
though both for those interested in health impacts
and those interested just in social and economic
impacts. Those interested in social and economic
outcomes are estimating incomplete cost–benefit
analysis by ignoring potential health benefits (or
costs) of the policies. From the perspective of health
researchers, ignoring these effects is unfortunate
because in cases (such as, perhaps education) the
health benefit of these nonhealth policies may in the
long run swamp the health effects of more targeted
health policies.
We also note that the decision analysis for whether
to support such policies is dramatically more diffi-
cult for these nonhealth policies, as evidenced by the
already difficult debates surrounding, for example,
welfare reform. We do not attempt here to balance
the health and other benefits against the larger sets
of costs involved; we simply highlight the areas in
which there may be substantial gradient-reducing
health benefits. A substantial task lies ahead for re-
searchers to tackle such issues in depth.
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Figure 2. (A) Depiction of typical current ladder relationship between SES and health. (B) Shrinking the gradient
through redistribution. (C) Investing in population-wide social determinants of health. (D) Reducing the gradient
by targeting risks and improving buffers among the lowest SES groups.
A further general difficulty of the evidence base is
that where some evidence is available, these studies
often speak only to possible effects of the general
construct under consideration (e.g., income) with
little evaluation of specific interventions needed to
influence the construct (e.g., earned-income tax
credits vs. cash welfare). But as Kawachi, Adler, and
Dow discuss in this volume, the specific mode of
transmission may well effect both the magnitude as
well as possibly even the sign of the health implica-
tions. Berkman20 has argued that in order to refine
proposed interventions it will be essential to bet-
ter understand the social and institutional contexts
and how they interact with individuals’ character-
istics to produce very different health impacts in
different settings. She further argues for a deeper
understanding of the etiologic period during which
individuals are most sensitive to intervention. As
discussed elsewhere in the volume, a great deal
of research has suggested that prenatal and early
childhood periods may be particularly important.
It has been further argued that from a cost–benefit
perspective investing in early life may yield much
greater returns than investing in interventions dur-
ing adulthood.21
The time dimension also deserves special atten-
tion in terms of the time needed for an interven-
tion to have the expected effects. Many low-SES in-
dividuals have been in low SES settings for years,
and their families and associated social networks
may have been in low SES conditions for genera-
tions. Although the evidence is overwhelming that
higher SES individuals have better health outcomes
than low SES individuals, it is not a simple task to
move an individual from one SES milieu to another.
Income support policies can raise an individual’s
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income dimension of SES, but raising income with-
out intervening on the many other dimensions of
that person’s SES (such as wealth, education, so-
cial capital, neighborhood, etc.) may have only lim-
ited benefits. In fact, increasing the dissonance be-
tween SES dimensions may even be harmful. Such
a concern is consistent with the Moving to Oppor-
tunity finding about a random low-income hous-
ing voucher allowing a move from a poor to a
nonpoor neighborhood: in that study, male youths
had worse physical health outcomes and engaged in
more risky behaviors after their move.22 Similarly,
unexpected negative health findings from positive
income shocks were discussed in Kawachi, Adler,
and Dow. It may be that the benefits of moving
to a higher income level will not be seen until the
next generation. This perspective is also consistent
with fetal programming and epigenetic research dis-
cussed earlier in the volume. Poverty researchers
have of course been attempting for decades to dis-
cover feasible poverty reduction policies within the
United States, thus we face with humility the task of
identifying appropriate poverty-reducing strategies
that improve health. It is to this set of policies that we
next turn as we begin the ladder-based health policy
taxonomy.
Raising SES of the lowest SES groups
The left-hand arrow in Figure 2B illustrates the ef-
fect on the gradient of policies that improve the
economic status of low SES populations, such as
reducing poverty. By moving low SES individuals
in a society up along the curve toward the right,
gradients are reduced. Raising their SES leads to a
tighter distribution of income in society, thus there
is less scope for SES disparities in health. Graphi-
cally, this is illustrated as compressing the bottom
of the ladder toward the middle, which shortens
the distance between the rungs (SES deciles) on the
ladder.
Examples
In the short run, programs that provide additional
income to the family may assist the family in climb-
ing up the ladder. These include transfer programs,
such as Temporary Assistance for Needy Families,
Supplemental Security Income, Supplemental Nu-
trition Assistance Program, and Special Supplemen-
tal Nutrition Program for Women, Infants, and
Children; tax policy, such as the Earned Income Tax
Credit; and minimum wage legislation. The health
outcome consequences of these policies have not
been extensively investigated; see Herd, House, and
Schoeni for a recent review of the health effects of in-
come transfer programs.23 Although many analysts
have a strong prior expectation that these should
improve health, the empirical literature has gen-
erated conflicting results as discussed by Kawachi,
Adler, and Dow. For example, evidence suggests that
some types of income may improve child health
outcomes24 while simultaneously raising adult obe-
sity.25 Studies on the impact of increasing income
on health have thus far been relatively short run,
however, leaving open the question of whether sus-
tained intervention over decades may yield more
unambiguously beneficial health results.
When considering interventions that may raise
SES over the course of generations, a more com-
monly considered type of intervention is educa-
tion. Several recent literature reviews of this topic
offer compelling quasi-experimental evidence on
health effects.26,27 Heckman has specifically argued
for the importance of investing in early education,
though there is little evidence to guide us regard-
ing long-term health benefits; Muennig et al. re-
port null effects of the Perry Preschool Project on
health, but the confidence intervals are large due
to the small sample size.28 Equally vexing is the
challenge in determining what dimension of educa-
tion should be given higher priority. Muennig and
Woolf have quantified health benefits versus costs
of smaller class size, finding that reducing class sizes
in kindergarten through grade 3 appears to be a
cost-effective way to improve health (QALYs), but
many more such studies will be needed before the
literature could hope to provide evidence-based rec-
ommendations.29 Given the strong disagreements
about the direct educational effects of various types
of educational interventions, we again should have
humility as we attempt to glean the most pro-
ductive educational investments in terms of health
outcomes.
Redistribution away from highest SES
Along with raising the bottom of the ladder, one
could develop policies that would shorten the top.
Those could be coupled, since one method of fi-
nancing poverty reduction is increasing taxes for
high SES individuals. As depicted in the right-hand
arrow of Figure 2B, this would have the further effect
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of moving the right tail of the SES distribution to-
ward the mean, thus again reducing scope for SES-
related health gradients but also lowering health of
the most advantaged. More generally, with the type
of nonlinear ladder depicted here characterized by
diminishing marginal health productivity of SES,
redistribution from high SES to low SES will reduce
SES health disparities and increase total health in the
population. Graphically, this is illustrated as short-
ening the top of the ladder, bringing those at upper
SES levels closer toward the mean.
Examples
Raising top marginal tax rates, and regulating exec-
utive pay, are two examples of such redistribution.
We are not aware of any evidence regarding direct
health consequences of these policies. It is plausible
that reducing the super wealthy could have spillover
health effects due to lower inequality, though as dis-
cussed in the Kawachi, Adler, and Dow chapter, the
evidence is weak on this point.
Reducing population-wide risk exposures
By reducing population-wide risk exposures, lower
SES individuals often experience disproportionate
benefits due to their higher vulnerability and lower
incomes. Graphically, such population-wide invest-
ments are depicted in Figure 2C as raising the entire
ladder equally, though in some cases we could expect
a larger rise for the low SES due to their greater risk.
It should be noted, however, that some population-
wide policies may differentially benefit those higher
on the ladder. To the extent that achieving health
benefits requires corollary action on the part of in-
dividuals, those higher on the ladder may be better
equipped to take advantage of the intervention or
policy. For example, smoking rates have dropped in
relation to a variety of policies, but the drop has
been sharper among those with more income and
more education.
Examples
Policies with population-wide consequences in-
clude clean air legislation, antidiscrimination poli-
cies, gas taxes, and tobacco taxes. A priori these could
be expected to have larger impacts on lower SES in-
dividuals. For example, Chay and Greenstone have
found that reduced air pollution disproportion-
ately lowered infant mortality among disadvantaged
populations.30
Targeted exposure reduction among low SES
Gradients exist in part due to higher risk exposures
among the low SES. If those exposures can be re-
duced, this would rotate up the left portion of the
ladder, thus reducing part of the negative health
consequences of low SES (Fig. 2D).
Examples
The workplace is one promising arena for pre-
vention to help reduce exposures to both occupa-
tional illnesses as well as toxic stress, as discussed
by Clougherty, Souza, and Cullen in this volume.
Another arena with much current active research is
that of neighborhoods. Interventions have been pro-
posed for improving low-income neighborhoods
by increased policing, expanding parks and recre-
ational opportunities, reducing liquor store licens-
ing, encouraging green grocers, etc. CDC’s Guide to
Community Preventive Services discusses evidence
reviews of some dimensions of these interventions.
In general, the evidence is not yet sufficient to rec-
ommend intervention according to classical statis-
tical criteria. This is an area in which many people
have strong theoretical priors about the likely ben-
efits of community intervention, thus many local
policy makers are ahead of the classical statistical ev-
idence currently, perhaps implicitly using Bayesian
policy analysis criteria to justify intervening before
the evidence base is built.
Buffering negative health consequences
of low SES
As discussed above, low SES individuals may have
fewer coping resources for buffering the adverse ef-
fects of shocks. Providing buffers can again result
in the left portion of the ladder rotating up in Fig-
ure 2D, thus reducing the health gradient across the
population.
Examples
A variety of buffers have been proposed to help pro-
tect low SES individuals from the negative health
consequences of their higher exposure risks, includ-
ing universal health insurance, paid sick leave poli-
cies, workplace control and autonomy, and social
support interventions. Health insurance is perhaps
the most important of these, as well as the most
studied, and the one with the largest welfare im-
pact.31 Another area that has been studied exten-
sively, is social support; there have even been recent
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randomized trials, although they have been largely
negative thus far, which is something of a caution
regarding the challenges in constructing actual in-
tervention programs to fit our hypothesized path-
ways.20
Strengthening the social safety net
The left tail of Figure 2A partly comprises indi-
viduals who in previous periods were higher on
the ladder but subsequently experienced negative
shocks, sometimes beyond their control, such as
recession-driven involuntary unemployment. Poli-
cies that strengthen the social safety net can prevent
individuals from experiencing precipitous drops
down the SES ladder. Over time, this can result in
fewer individuals at the lower end of the ladder, thus
having the same net effect as policies that raise the
lower part of the SES distribution as depicted in
Figure 2B.
Examples
Unemployment insurance and job training pro-
grams are crucial examples of safety net policies.
But while the health consequences of unemploy-
ment have been extensively studied and discussed
elsewhere in this volume, there is in fact little evi-
dence regarding the extent to which particular fea-
tures of unemployment insurance may or may not
protect health.
Conclusion
Moving forward, there is great scope for generating
additional relevant analysis of specific policies and
interventions to inform future agenda setting. To
the extent that existing policies can be evaluated us-
ing strong designs with perhaps quasi-experimental
methods, this should by all means be encouraged.
The evaluation of policies in nonhealth sectors,
including those that we have discussed in this pa-
per, may be facilitated by the use of “health impact
assessments (HIAs).” HIAs are similar to EIAs, en-
vironmental impact assessments. HIAs evaluate the
effects of a given policy on health of the affected
population while EIAs focus primarily on the im-
pact on the physical environment. HIAs are cur-
rently being used primarily in Europe. However,
there is growing interest in and application of them
in the United States32 where they have largely been
applied to municipal policies thus far. For example,
HIAs have estimated the health impact on the resi-
dents of San Francisco of a city ordinance requiring a
living wage rather than a minimum wage,33 and the
health impact on the Inupiat populations in Alaska’s
North Slope of the development of oil fields.34 The
methodology could potentially be used for state or
federal policy as well. At whatever level HIAs are
done, they will require an evidence base to inform
the evaluation of health effects. There are some early
efforts to undertake to acquire and systematize such
information.35 However, this is a formidable task
and much work remains to be done.
As the Health Impact Assessment field matures,
practitioners as well as researchers will likely be con-
tributing substantially to our evidence base. Their
work would be further enhanced by closer atten-
tion to the principles of cost–benefit and cost-
effectiveness analysis, which have been refined in
recent decades for related studies. It would also
benefit the field to develop a body to serve as an
information clearing house of completed studies on
social determinants, to identify ongoing efforts, and
help match relevant interventions with potential
researchers.
While additional research is needed, we believe
there is ample existing evidence to support our pri-
ors that social and economic factors have a first-
order effect on improving population health. The
research literature has firmly established many times
over the existence of socioeconomic gradients in
health, and a great deal of research suggests that
these are often due to causal effects of socioeco-
nomic factors on health. For many policies, these
benefits to health augment well-established bene-
fits in social and economic outcomes such as labor
market earnings and income. Moreover, we have
argued that lack of randomized trials should not in
and of itself preclude investments in reducing health
gradients. In settings outside the United States,
agenda setters have successfully promoted social de-
terminants policies despite the equivocal evidence.
Recently, the Robert Wood Johnson Foundation’s
Commission for a Healthier America released a set
of recommendations agreed upon by their bipar-
tisan commission as having evidence sufficient for
policy recommendation, including a focus on early
childhood education.36 The commission, however,
did not take on the issue of poverty reduction as a
strategy for improving health and reducing gradi-
ents. A future effort to focus on ways to improve
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health by reducing child poverty could yield mean-
ingful progress in the policy realm.
The challenge in translating this evidence into
policy is in identifying specific policy levers that
could in fact substantially improve health and pass
the cost-benefit test. Our reading of the evidence
is that if socioeconomic disparities in U.S. popula-
tion health are to be substantially improved by the
next generation, investing in all manner of educa-
tion is broadly speaking one of the most promising
approaches. Supplementing this with income sup-
port policies, particularly surrounding pregnancy
and early childhood, could also have substantial
benefits according to our understanding of the cur-
rent literature. Current national efforts to reduce
uninsurance could rectify some important dimen-
sions of current gradients, but preparing for a future
national debate over expanded educational attain-
ment should be a high priority for health policy
researchers interested in the social determinants of
population health.
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